|
|
|
|
Vol. 56, Issue 4, 714-719, October 1999
Departments of Pharmacology and Toxicology (R.A.M.H. van A., J.G.P.P., F.G.M.R.), Biochemistry (J.B.K.), and Cell Physiology (C.H. van O.), University of Nijmegen, the Netherlands
| |
Summary |
|---|
|
|
|---|
The present study examined how the multidrug resistance protein
(MRP) 2, which is an ATP-dependent anionic conjugate
transporter, also mediates transport of the chemotherapeutic cationic
drug vinblastine (VBL). We show that ATP-dependent
[3H]VBL (0.2 µM) uptake into membrane vesicles from Sf9
cells infected with a baculovirus encoding rabbit Mrp2 (Sf9-Mrp2) was
similar to vesicles from mock-infected Sf9 cells (Sf9-mock) but could be stimulated by reduced glutathione (GSH) with a half-maximum stimulation of 1.9 ± 0.1 mM. At 5 mM GSH, initial ATP-dependent [3H]VBL uptake rates were saturable with an apparent
Km of 1.5 ± 0.3 µM. The inhibitory
effect of VBL on Mrp2-mediated ATP-dependent transport of the anionic
conjugate [3H]leukotriene C4 was
potentiated by increasing GSH concentrations. Membrane vesicles from
Sf9-Mrp2 cells exhibited a ~7-fold increase in initial GSH uptake
rates compared with membrane vesicles from Sf9-mock cells. Uptake of
[3H]GSH was osmotically sensitive, independent of ATP,
and was trans-inhibited by GSH. The anionic conjugates
estradiol-17
-D-glucuronide and leukotriene C4 cis-inhibited
[3H]GSH uptake but only in the presence of ATP.
Whereas ATP-dependent [3H]VBL uptake was stimulated by
GSH, VBL did not affect [3H]GSH uptake. Our results show
that GSH is required for Mrp2-mediated ATP-dependent VBL transport and
that Mrp2 transports GSH independent of VBL.
| |
Introduction |
|---|
|
|
|---|
The
multidrug resistance protein (MRP) 2 (or canalicular multispecific
organic anion transporter) is an ATP-dependent anionic conjugate
transporter, which is expressed in small intestine and apical
(canalicular) membranes of hepatocytes and renal proximal tubules (for
review, see Keppler and König, 1997
). Substrates of MRP2 include
glutathione S-conjugates, such as
S-(dinitrophenyl)-glutathione (DNP-SG),
S-(prostaglandin A1)-glutathione, and
leukotriene C4 (LTC4) and
glucuronide conjugates of bilirubin and estradiol (Jedlitschky et al.,
1997
; Madon et al., 1997
; Evers et al., 1998
; Ito et al., 1998
; van
Aubel et al., 1998
). MRP2 belongs to a branch of at least six MRPs
(MRP1-MRP6) within the superfamily of ATP-binding cassette proteins
(see for latest update http://www.med.rug.nl/mdl/tab3.htm). Involvement
in the phenotype of multidrug resistance, however, has only been proven
for MRP1 because it is frequently overexpressed in various
drug-selected cancer cell lines, and transfection of drug-sensitive
cells with an MRP1 cDNA results in resistance to various drugs (Cole and Deeley, 1998
). Recently, overexpression of
MRP2 mRNA and MRP2 protein levels has been found in a few
cancer cell lines selected for cis-diamminedichloroplatin
(Kool et al., 1997
). Down-regulation of endogenous MRP2 protein levels
in HepG2 cells via antisense transfection reduces resistance to various chemotherapeutic drugs, including vincristine (VCR) and
cis-diamminedichloroplatin (Koike et al., 1997
). MDCKII
cells stably transfected with an MRP2 cDNA show enhanced
vinblastine (VBL) transport across the apical membrane (Evers et al.,
1998
).
The mechanism by which MRP2 mediates transport of cationic
chemotherapeutic drugs is unknown. Because MRP1 requires reduced glutathione (GSH) for ATP-dependent VCR uptake into membrane vesicles (Loe et al., 1996
), MRP2-mediated drug transport might also depend on
GSH. Furthermore, it has been suggested that GSH itself is an MRP2
substrate, but reports are contradictory (Oude Elferink et al., 1989
;
Fernandez-Checa et al., 1992
). The Eisai hyperbilirubinemic (EHBR) and
transport-deficient TR
rat strains, respectively,
which lack functional Mrp2, are characterized by hyperbilirubinemia as
well as low biliary GSH contents compared with wild-type rats (Oude
Elferink et al., 1989
; Takikawa et al., 1991
; Keppler and König,
1997
). However, GSH uptake into EHBR liver canalicular membrane
vesicles has been reported to be similar to wild-type liver canalicular
membrane vesicles (Fernandez-Checa et al., 1992
). Furthermore, both
wild-type and EHBR canalicular membrane vesicles only harbor
ATP-independent GSH transport systems, suggesting that Mrp2 is not
involved in GSH transport (Fernandez-Checa et al., 1992
; Ballatori and
Dutczak, 1994
).
The purpose of this study was to investigate the mechanism by which
MRP2 mediates ATP-dependent transport of the cationic drug VBL. Using
membrane vesicles from Sf9 cells overexpressing rabbit Mrp2 as
described previously (van Aubel et al., 1998
), we determined uptake of
[3H]VBL with emphasis on a putative role for
GSH. In addition, we investigated whether GSH itself is an Mrp2
substrate and how VBL and GSH affect Mrp2-mediated ATP-dependent uptake
of [3H]LTC4.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
[G-3H]VBL sulfate (15.5 Ci/mmol) was purchased from Amersham International (Buckinghamshire,
UK). [14, 15, 19, 20-3H]LTC4 (165 Ci/mmol)
and [glycine-2-3H]GSH (44.8 Ci/mmol) were
purchased from NEN Life Science Products (Hoofddorp, the Netherlands).
Estradiol-17
-D-[3H]glucuronide
(E217
G),
LTC4, glucuronate, S-methyl-GSH, GSH, ATP, dithiothreitol (DTT), and VBL were purchased from Sigma
(Zwijndrecht, the Netherlands). Acivicin was purchased from ICN
Biochemicals (Cleveland, OH). Creatine phosphate and creatine kinase
were purchased from Boehringer Mannheim (Almere, the Netherlands).
Glass fiber GF/F filters were purchased from Whatman (Omnilabo
International, Breda, the Netherlands). ME-25 membrane filters were
purchased from Schleicher & Schuell (Dassel, Germany).
3-([{3-(2-[7-Chloro-2-quinolinyl]ethenyl)phenyl}-{(3-dimethyl-amino-3-oxopropyl)-thio}-methyl]thio)propanoic acid (MK571) was a generous gift of Dr. A. W. Ford-Hutchinson (Merck
Frosst, Center for Therapeutic Research, Quebec, Canada).
Expression of Mrp2 in Sf9 Cells and Isolation of Membrane
Vesicles.
Sf9 cells (106/ml) were grown as
100-ml suspension cultures and infected for 3 days at a multiplicity of
infection of 1 to 5 with a recombinant baculovirus encoding rabbit Mrp2
(Sf9-Mrp2) as described recently (van Aubel et al., 1998
). For control
experiments, Sf9 cells were infected with a baculovirus encoding the
-subunit of rat
H+/K+ ATPase (Sf9-mock).
Membrane vesicles were isolated as described (van Aubel et al., 1998
).
Briefly, cells were collected, resuspended in hypotonic buffer (0.5 mM
sodium phosphate and 0.1 mM EDTA, pH 7.0) and centrifuged at
100,000g for 30 min. The pellet of crude membranes was
resuspended in TS buffer (10 mM Tris-HEPES and 250 mM sucrose, pH 7.4)
and centrifuged at 12,000g for 10 min. The postnuclear
supernatant was centrifuged at 100,000g for 40 min, and the
pellet obtained was resuspended in TS buffer, layered over 38% sucrose
in 5 mM HEPES/KOH (pH 7.4), and centrifuged at 100,000g for
120 min. The interphase was collected, homogenized, and centrifuged at
100,000g for 40 min. The resulting pellet was resuspended in
TS buffer and passed through a 27-gauge needle 30 times. Membrane
vesicles were frozen and stored at
80°C until use.
Transport Studies.
Uptake of [3H]VBL
into membrane vesicles was performed as described (Horio et al., 1988
;
van Aubel et al., 1998
), with modifications. Briefly, membrane vesicles
(20 µg of protein equivalent) were thawed for 1 min at 37°C and
added to prewarmed TS buffer supplemented with an ATP-regeneration mix
(4 mM ATP, 20 mM MgCl2, 10 mM creatine phosphate,
and 100 µg/ml creatine kinase) and 0.2 µM
[3H]VBL in a final volume of 60 µl. The
reaction mixture was incubated at 37°C, and at indicated times,
samples were taken from the mixture, diluted in 1 ml of ice-cold TS
buffer and filtered through Whatman GF/F filters [soaked overnight in
5% (w/v) BSA at 37°C] using a filtration device (Millipore Corp.,
Bedford, MA). Filters were washed once with 5 ml of ice-cold TS buffer
and dissolved in liquid scintillation fluid to determine the bound
radioactivity. Uptake of
[3H]LTC4 at 2 nM was
performed as described (van Aubel et al., 1998
). Uptake of
[3H]GSH at 37°C was performed according to
the same procedure as for
[3H]LTC4, except that 5 mM DTT was added at every GSH concentration used and that samples were
filtered through ME-25 membrane filters. Uptake of GSH was not affected
by 250 µM acivicin, indicating negligible activity of
-glutamyltransferase in membrane vesicles of Sf9 cells. In all
uptake experiments, net ATP-dependent transport was calculated by
subtracting values in the absence of ATP from those in the presence of
ATP. Measurements were corrected for the amount of ligand bound to the
filters (usually <2% of total radioactivity).
| |
Results |
|---|
|
|
|---|
We investigated uptake of [3H]VBL into
membrane vesicles prepared from Sf9 cells infected with a baculovirus
containing a rabbit mrp2 cDNA (Sf9-Mrp2). We have recently
shown that these membrane vesicles contain functional Mrp2 as assessed
by uptake studies with
[3H]LTC4 and
([3H]E217
G)
(van Aubel et al., 1998
). As shown in Table
1, ATP-dependent uptake of 0.2 µM
[3H]VBL into Sf9-Mrp2 membrane vesicles did not
differ from uptake into membrane vesicles from Sf9 cells infected with
a baculovirus encoding the
-subunit of rat
H+/K+ ATPase (Sf9-mock). In
the presence of 5 mM GSH, however, ATP-dependent uptake of
[3H]VBL into Sf9-Mrp2 membrane vesicles
increased 5-fold. The leukotriene D4-receptor
antagonist MK571 (Jones et al., 1989
), which is an inhibitor of
Mrp2-mediated transport (Büchler et al., 1996
; van Aubel et al.,
1998
), inhibited GSH-stimulated ATP-dependent
[3H]VBL uptake by ~60%.
S-Methyl-GSH also increased ATP-dependent [3H]VBL uptake, however, this stimulation was
55% of uptake with GSH. Glucuronate and DTT, which was used to
maintain GSH in the reduced form (Ballatori and Dutczak, 1994
), did not
stimulate uptake.
|
In the presence of GSH and ATP, Sf9-Mrp2 membrane vesicles exhibited
time-dependent uptake of [3H]VBL (Fig.
1A). In the absence of ATP,
GSH-stimulated [3H]VBL uptake into Sf9-Mrp2
membrane vesicles was low. For Sf9-Mrp2 membrane vesicles, initial
uptake rates of net GSH-stimulated ATP-dependent
[3H]VBL were 5.2 ± 0.7 pmol/mg/20 s (Fig.
1B). In contrast, transport into Sf9-mock membrane vesicles was
independent of time (4.9 ± 0.5 pmol/mg) and probably reflects
nonspecific membrane binding. To confirm that vesicle-associated
increase of ligand reflects transport into a vesicular space, the
effect of medium osmolarity on [3H]VBL uptake
was investigated (Fig. 2). GSH-stimulated
ATP-dependent [3H]VBL uptake into Sf9-Mrp2
membrane vesicles decreased linearly with increasing concentrations of
sucrose. Because vesicle space decreases with increasing osmolarity,
extrapolation of the data to zero vesicle space indicates that 5.0 ± 0.6 pmol VBL/mg protein is bound to the vesicle membrane.
|
|
To further investigate GSH-stimulated VBL transport by Mrp2, initial
transport rates were determined at various concentrations of
[3H]VBL (Fig.
3A). In the presence of 5 mM GSH, initial
ATP-dependent [3H]VBL uptake rates increased
with increasing VBL concentrations. Fitting of the obtained data
according to the Michaelis-Menten equation revealed a
Km of 1.5 ± 0.3 µM and
Vmax of 89 ± 6 pmol/mg/20 s. We also
investigated the GSH concentration dependence of Mrp2-mediated ATP-dependent VBL transport (Fig. 3B). Initial ATP-dependent
[3H]VBL uptake rates increased with increasing
GSH concentrations to a maximum at 10 mM. According to Michaelis-Menten
kinetics, half-maximum stimulation was determined at a GSH
concentration of 1.9 ± 0.1 mM.
|
We investigated the effect of GSH and VBL on ATP-dependent uptake of
the high-affinity substrate LTC4 into Sf9-Mrp2
membrane vesicles. As shown in Fig. 4,
initial rates of ATP-dependent
[3H]LTC4 uptake were not
inhibited but rather stimulated by GSH at concentrations of 0.1, 1, and
5 mM. VBL (0.1 mM) was only a poor inhibitor of initial
[3H]LTC4 uptake rates.
However, the inhibitory effect of VBL (20%) was greatly stimulated in
the presence of 0.1, 1, and 5 mM GSH to 72, 82, and 95%, respectively.
|
To investigate whether GSH itself is an Mrp2 substrate, we measured
uptake of [3H]GSH at concentrations of 0.1 and
5 mM. Sf9-Mrp2 membrane vesicles exhibited time-dependent uptake of
[3H]GSH at 0.1 mM, however, uptake was only
modestly increased as compared with uptake into Sf9-mock membrane
vesicles (Fig. 5A). At 5 mM,
[3H]GSH was taken up into Sf9-Mrp2 membrane
vesicles with an initial rate of 1.4 ± 0.3 nmol/mg/min, which was
~7-fold higher compared with initial rates in Sf9-mock membrane
vesicles (Fig. 5B). In the presence of ATP, time-dependent uptake of
[3H]GSH (0.1 or 5 mM) into Sf9-Mrp2 and
Sf9-mock membrane vesicles was not significantly different from uptake
in the absence of ATP (Fig. 5, A and B). Uptake of
[3H]GSH was sensitive to osmolarity, indicating
that vesicle-associated [3H]GSH levels
represent true uptake into membrane vesicles rather than binding to the
vesicle membrane (Fig. 5C). Preloading of Sf9-Mrp2 membrane vesicles
with 5 mM GSH reduced initial [3H]GSH uptake
rates by ~85% either in the presence or absence of ATP (Table
2). Initial
[3H]GSH uptake rates were also inhibited by
LTC4, E217
G,
and MK571 but only in the presence of ATP, whereas
S-methyl-GSH had no effect (Table 2).
|
|
Recently, Loe et al. (1998)
demonstrated that VCR stimulates GSH uptake
into membrane vesicles from MRP1-transfected HeLa cells,
providing evidence for a VCR/GSH cotransport mechanism. In view of a
possible VBL/GSH cotransport mechanism by Mrp2, we investigated the
effect of various VBL concentrations on uptake of
[3H]GSH into Sf9-Mrp2 membrane vesicles.
However, the initial uptake rate of [3H]GSH at
0.1 mM (95 ± 12 pmol/mg/min; n = 2) or 5 mM
(1.3 ± 0.2 nmol/mg/min; n = 2) was not affected
by either 0.2 µM, 10 µM, or 0.1 mM VBL (Table 2; data not shown).
Furthermore, none of these VBL concentrations affected uptake of
[3H]GSH at 5 mM for 4 min (data not shown).
| |
Discussion |
|---|
|
|
|---|
The present study demonstrates that the ATP-dependent anionic
conjugate transporter Mrp2 requires GSH for ATP-dependent transport of
the cationic drug VBL. S-Methyl-GSH also stimulated
ATP-dependent VBL transport but to a lesser extent than GSH, whereas
glucuronate was not able to induce VBL transport. These results are in
line with previous reports showing that MRP1-mediated VCR transport is
stimulated by GSH and to a lesser extent by S-methyl-GSH but not by glucuronate (Loe et al., 1996
, 1998
). Furthermore, we show that
stimulation of Mrp2-mediated ATP-dependent VBL transport by GSH is
saturable, with a half-maximum stimulation at 1.9 mM. In the presence
of 5 mM GSH, saturability of transport is observed at increased VBL
concentrations, with a Km of 1.5 µM.
Moreover, the small inhibitory effect of VBL on Mrp2-mediated
ATP-dependent [3H]LTC4
transport was potentiated by increasing the GSH concentration.
Second, we show that membrane vesicles from Sf9-Mrp2 cells exhibited a
~7-fold increase in initial GSH uptake rates compared with membrane
vesicles from Sf9-mock cells. Uptake of GSH was sensitive to medium
osmolarity independent of ATP and almost completely abolished when
membrane vesicles were preloaded with GSH. Initial GSH uptake rates in
Sf9-Mrp2 membrane vesicles were inhibited by the anionic conjugates
LTC4 and
E217
G, but only in the presence of
ATP. These results suggest that Mrp2 is permeable for GSH and that the
site for GSH permeability interacts with the site for active transport
of anionic conjugates. In this respect, MK571 inhibits both
Mrp2-mediated ATP-dependent anionic conjugate transport and
ATP-independent GSH transport (van Aubel et al., 1998
; this study).
Similar to our results, GSH permeability has recently been shown for
the cystic fibrosis transmembrane conductance regulator, which
belongs to the MRP branch of ATP-binding cassette transporters (Linsdell and Hanrahan, 1998
). Alternatively, Mrp2 itself may not be
involved in GSH transport but may regulate an endogenous ATP-independent GSH transporter. Such a regulatory mechanism for Mrp2
has been proposed based on results from uptake studies with liver
canalicular membrane vesicles (Fernandez-Checa et al., 1992
; Ballatori
and Dutczak, 1994
; Mittur et al., 1998
). Radiation inactivation of
canalicular GSH transport has indicated the complexity of low-affinity GSH transport, which involves multiple putative transporters, including
presumably Mrp2 (Mittur et al., 1998
). Furthermore, low-affinity GSH
uptake into liver canalicular membrane vesicles is
cis-inhibited by DNP-SG in the absence of ATP but
trans-stimulated by DNP-SG in the presence of ATP
(Fernandez-Checa et al., 1992
; Ballatori and Dutczak, 1994
). The
characteristics of this Mrp2-regulated GSH transport, however, are
different from our results, because anionic conjugates inhibited GSH
uptake into Sf9-Mrp2 membrane vesicles in the presence of ATP, whereas
they did not affect uptake in the absence of ATP.
A recent report by Paulusma et al. (1999)
is at variance with the
hypothesis of Mrp2 as both an ATP-dependent anionic conjugate transporter and an ATP-independent GSH transporter. These authors demonstrated that inhibition of ATP synthesis in
Mrp2-transfected MDCKII cells greatly reduced efflux of both
DNP-SG and GSH across the apical membrane (Evers et al., 1998
; Paulusma
et al., 1999
). Nonetheless, a difference in uptake of GSH between
membrane vesicles of transfected and parental cells either in the
presence or absence of ATP was undetectable (Paulusma et al., 1999
).
Similar contradictory results obtained with intact cells and isolated
membrane vesicles have been reported for MRP1. Although expression
levels of MRP1 correlate with efflux of GSH from intact cells (Zaman et
al., 1995
; Rappa et al., 1997
; Paulusma et al., 1999
), MRP1-mediated uptake of GSH into membrane vesicles either in the presence or absence
of ATP could not be demonstrated (Leier et al., 1996
; Loe et al.,
1998
). It has recently been suggested that MRP1 and Mrp2 might mediate
GSH efflux from intact cells in the form of a short-lived complex with
an intracellular compound, which is lacking in preparations of membrane
vesicles (Zaman et al., 1995
; Paulusma et al., 1999
). Such a mechanism
would explain why Mrp2-deficient rats have very low biliary GSH levels,
although GSH uptake into EHBR canalicular membrane vesicles is intact
(Oude Elferink et al., 1989
; Fernandez-Checa et al., 1992
). On the
other hand, membrane vesicle preparations from various cell lines and
tissues may be unsuitable for detecting GSH uptake because of their
mixed orientation and possible leakage. Recently, Rebbeor et al.
(1998a)
have demonstrated GSH uptake into yeast sec6-4
membrane vesicles, which are orientated almost exclusively inside out
(Ambesi et al., 1997
). Uptake of GSH into these vesicles was saturable
(Km = 15-20 mM), competitively inhibited
by DNP-SG (Ki ~ 0.2 mM), and dependent on
ATP. A further study identified the yeast cadmium factor-1 (YCF1), a
yeast ortholog of mammalian MRP1 and MRP2 (Li et al., 1996
), as the
major contributor to ATP-dependent GSH transport (Rebbeor et al.,
1998b
). However, membrane vesicles from wild-type yeast also show low
levels of ATP-independent GSH uptake, and at present it is unknown
whether YCF1 or a different transporter is involved (Rebbeor et al.,
1998a
,b
).
The physiological significance of MRP2-mediated GSH secretion into bile
and urine is not clear. Biliary and urinary GSH may provide protection
against oxidative damage and, in addition, may be a source for
glutamate, glycine, and cysteine after degradation of GSH by
extracellular membrane-bound peptidases (Ookhtens and Kaplowitz, 1998
).
Furthermore, urinary GSH may account for detoxification of agents that
enter the urine directly via glomerular filtration. Besides MRP2, other
transport proteins also are involved in biliary GSH secretion
(Ballatori and Rebbeor, 1998
). In liver canalicular membranes, the
putative low- and high-affinity ATP-independent GSH transporters both
have an estimated molecular mass of ~70 kDa (Mittur et al., 1998
).
Although their molecular identity is unknown, these transporters might
be canalicular isoforms of the 74-kDa sinusoidal organic anion
transporting polypeptide (Oatp1), which functions as a GSH/organic
solute exchanger (Ballatori and Rebbeor, 1998
).
In this study, we tried to address the mechanism by which GSH affects
Mrp2-mediated ATP-dependent VBL transport. Possible explanations for
the effect of GSH are spontaneous formation of a
glutathione-S-conjugate, a cotransport mechanism, or an
indirect interaction. So far, conjugates of GSH with vinca
alkaloids, such as VCR and VBL, have not been demonstrated (Tew, 1994
;
Ban et al., 1996
). Furthermore, HPLC analysis of the products excreted by MRP1-transfected SW-1573/S1 cells after preloading with
VCR only revealed unmodified drugs (Zaman et al., 1995
). Thus, either GSH is cotransported with VBL or GSH indirectly stimulates
ATP-dependent VBL transport. GSH stimulates Mrp2-mediated ATP-dependent
VBL transport with an apparent half-maximum stimulation at ~2 mM. A
similar value (2.7 mM) was found for GSH-stimulated ATP-dependent daunorubicin transport by MRP1 (Renes et al., 1999
). The transport affinity of GSH for MRP2/Mrp2 appears to be 10-fold lower (~20 mM),
which is in the same range as reported for YCF1 (Rebbeor et al., 1998b
;
Paulusma et al., 1999
). This suggests that VBL enhances the affinity of
GSH for Mrp2, but we could not demonstrate that VBL induces
Mrp2-mediated GSH transport, as one would expect for a cotransport
mechanism. Loe et al. (1998)
recently have shown both GSH-stimulated
VCR and VCR-stimulated GSH uptake into membrane vesicles of HeLa cells
overexpressing human MRP1, suggesting a VCR/GSH cotransport mechanism.
VBL also stimulated GSH uptake into MRP1-enriched membrane vesicles,
although to a lesser degree than VCR (Loe et al., 1998
). With respect
to our results, we cannot exclude that it is impossible to detect a
VBL-dependent stimulation of GSH transport above the background of GSH
uptake, because of the relatively low affinity and high
Vmax of the latter process. However, even
if VBL does not stimulate GSH transport, we conclude from our data that
Mrp2-mediated GSH transport does not require the cotransport of VBL.
| |
Footnotes |
|---|
Received January 20, 1999; Accepted May 21, 1999
J.B.K. is supported by the Netherlands Organization for Scientific Research through Grant 805-05.041.
Send reprint requests to: Dr. F. G. M. Russel, University of Nijmegen, Department of Pharmacology and Toxicology 233, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands. E-mail: F.Russel{at}farm.kun.nl
| |
Abbreviations |
|---|
MRP, multidrug resistance protein;
LTC4, leukotriene C4;
VBL, vinblastine;
VCR, vincristine;
GSH, reduced glutathione;
E217
G, estradiol-17
-D-glucuronide;
DNP-SG, S-dinitrophenyl-glutathione;
EHBR, Eisai
hyperbilirubinemic rat strain;
DTT, dithiothreitol;
MK571, 3-([{3-(2-[7-chloro-2-quinolinyl]ethenyl)phenyl}-{(3-dimethyl-amino-3-oxopropyl)-thio}-methyl]thio)propanoic
acid;
YCF1, yeast cadmium factor-1.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Matsushima, K. Maeda, H. Hayashi, Y. Debori, A. H. Schinkel, J. D. Schuetz, H. Kusuhara, and Y. Sugiyama Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine Mol. Pharmacol., May 1, 2008; 73(5): 1474 - 1483. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. K. El-Sheikh, J. J. M. W. van den Heuvel, J. B. Koenderink, and F. G. M. Russel Interaction of Nonsteroidal Anti-Inflammatory Drugs with Multidrug Resistance Protein (MRP) 2/ABCC2- and MRP4/ABCC4-Mediated Methotrexate Transport J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 229 - 235. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ninomiya, K. Ito, R. Hiramatsu, and T. Horie Functional Analysis of Mouse and Monkey Multidrug Resistance-Associated Protein 2 (Mrp2) Drug Metab. Dispos., December 1, 2006; 34(12): 2056 - 2063. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Deeley, C. Westlake, and S. P. C. Cole Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiol Rev, July 1, 2006; 86(3): 849 - 899. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Hopper-Borge, Z.-S. Chen, I. Shchaveleva, M. G. Belinsky, and G. D. Kruh Analysis of the Drug Resistance Profile of Multidrug Resistance Protein 7 (ABCC10): Resistance to Docetaxel Cancer Res., July 15, 2004; 64(14): 4927 - 4930. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Wright and W. H. Dantzler Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport Physiol Rev, July 1, 2004; 84(3): 987 - 1049. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Lou, M. Ookhtens, A. Stolz, and N. Kaplowitz Chelerythrine stimulates GSH transport by rat Mrp2 (Abcc2) expressed in canine kidney cells Am J Physiol Gastrointest Liver Physiol, December 1, 2003; 285(6): G1335 - G1344. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Gerk and M. Vore Regulation of Expression of the Multidrug Resistance-Associated Protein 2 (MRP2) and Its Role in Drug Disposition J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 407 - 415. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Terlouw, C. Graeff, P. H. E. Smeets, G. Fricker, F. G. M. Russel, R. Masereeuw, and D. S. Miller Short- and Long-Term Influences of Heavy Metals on Anionic Drug Efflux from Renal Proximal Tubule J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 578 - 585. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. M. H. van Aubel, P. H. E. Smeets, J. G. P. Peters, R. J. M. Bindels, and F. G. M. Russel The MRP4/ABCC4 Gene Encodes a Novel Apical Organic Anion Transporter in Human Kidney Proximal Tubules: Putative Efflux Pump for Urinary cAMP and cGMP J. Am. Soc. Nephrol., March 1, 2002; 13(3): 595 - 603. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Yang and C. E. Hill Nifedipine modulation of biliary GSH and GSSG/ conjugate efflux in normal and regenerating rat liver Am J Physiol Gastrointest Liver Physiol, July 1, 2001; 281(1): G85 - G94. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. M. H. Van Aubel, J. G. P. Peters, R. Masereeuw, C. H. Van Os, and F. G. M. Russel Multidrug resistance protein Mrp2 mediates ATP-dependent transport of classic renal organic anion p-aminohippurate Am J Physiol Renal Physiol, October 1, 2000; 279(4): F713 - F717. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zeng, G. Liu, P. A. Rea, and G. D. Kruh Transport of Amphipathic Anions by Human Multidrug Resistance Protein 3 Cancer Res., September 1, 2000; 60(17): 4779 - 4784. [Abstract] [Full Text] |
||||
![]() |
J. F. Rebbeor, G. C. Connolly, J. H. Henson, J. L. Boyer, and N. Ballatori ATP-dependent GSH and glutathione S-conjugate transport in skate liver: role of an Mrp functional homologue Am J Physiol Gastrointest Liver Physiol, August 1, 2000; 279(2): G417 - G425. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. M. H. Van Aubel, R. Masereeuw, and F. G. M. Russel Molecular pharmacology of renal organic anion transporters Am J Physiol Renal Physiol, August 1, 2000; 279(2): F216 - F232. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Liu, R. Sanchez-Fernandez, Z.-S. Li, and P. A. Rea Enhanced Multispecificity of Arabidopsis Vacuolar Multidrug Resistance-associated Protein-type ATP-binding Cassette Transporter, AtMRP2 J. Biol. Chem., March 16, 2001; 276(12): 8648 - 8656. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||